patent/EP-0303064-B1

Predicate	Object
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755
classificationIPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
filingDate	1988-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate	1993-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate	1993-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	EP-0303064-B1
titleOfInvention	Phospholipid affinity purification of factor viii:c
abstract	Affinity purification of Factor VIII:C, both plasma derived and genetically engineered and fusion products thereof, using coupled phosphatidylserine (PS) as the predominant phospholipid (PH) results in a high degree of purity of Factor VIII:C, similar to that previously demonstrated with monoclonal antibodies specific to either Factor VIII:C or von Willebrand factor. Phospholipids that can be used in combination with PS are phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
priorityDate	1987-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411706 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6323481 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136010750 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128695397 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8102

Total number of triples: 21.